Skip to main content

Phil Febbo

Illumina has appointed Phil Febbo as chief medical officer. Starting March 26, 2018, Febbo will be responsible for developing and executing on Illumina's strategy to drive genomic testing into healthcare practice.

Prior to Joining Illumina, Febbo has served as CMO at Genomic Health, and before that he served as professor of medicine and urology at the University of California, San Francisco, where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer. While at UCSF, Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. He holds a BA degree in biology from Dartmouth College, received his MD at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital.